MedTrace Logo

Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout

NCT01078389 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 314

Last updated 2014-09-10

Study results available
· View outcomes & findings →

Summary

This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.

Conditions

  • Joint Damage

Interventions

DRUG

Febuxostat

Febuxostat capsules

DRUG

Placebo for Febuxostat

Febuxostat placebo-matching capsules

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078389 on ClinicalTrials.gov